Table 3.
Selected ongoing interventional trials listed on ClinicalTrials.gov (* actual and ** estimated enrollment).
| NCT Number | Tumor Entity | Autophagy Modulator |
Combination with… | Clinical Phase | Enrollment | Registration |
|---|---|---|---|---|---|---|
| NCT03037437 | Hepatocellular cancer | HCQ | Sorafenib | II | 68 ** | https://ClinicalTrials.gov/show/NCT03037437, accessed on 1 October 2021 |
| NCT04214418 | Gastrointestinal cancer | HCQ | Cobimetinib, Atezolizumab |
I/II | 175 ** | https://ClinicalTrials.gov/show/NCT04214418, accessed on 1 October 2021 |
| NCT04386057 | Pancreatic cancer (advanced) | HCQ | LY3214996 | II | 52 ** | https://ClinicalTrials.gov/show/NCT04386057, accessed on 1 October 2021 |
| NCT05036226 | Prostate Cancer (recurrent), solid tumors | HCQ | Metformin, Sirolimus, Nelfinavir, Dasatinib |
I/II | 76 ** | https://ClinicalTrials.gov/show/NCT05036226, accessed on 1 October 2021 |
| NCT02339168 | Prostate cancer | Metformin | Enzalutamide | I | 24 * | https://ClinicalTrials.gov/show/NCT02339168, accessed on 1 October 2021 |
| NCT01506973 | Adenocarcinoma (advanced, metastatic) | HCQ | Gemcitabine, Abraxane | I/II | 119 * | https://ClinicalTrials.gov/show/NCT01506973, accessed on 1 October 2021 |
| NCT04566133 | Cholangiocarcinoma | HCQ | Trametinib | II | 30 ** | https://ClinicalTrials.gov/show/NCT04566133, accessed on 1 October 2021 |
| NCT02042989 | Advanced cancers | MLN9708, Vorinostat | I | 68 * | https://ClinicalTrials.gov/show/NCT02042989, accessed on 1 October 2021 | |
| NCT01023737 | Malignant solid tumors | HCQ | Vorinostat | I | 72 * | https://ClinicalTrials.gov/show/NCT01023737, accessed on 1 October 2021 |
| NCT04333914 | Hematological or solid tumor (advanced, metastatic) | Autophagy inhibitor (GNS651) | Standard of care, Avdoralimab, Monalizumab | II | 219 ** | https://ClinicalTrials.gov/show/NCT04333914, accessed on 1 October 2021 |
| NCT03774472 | Breast Cancer | HCQ | Letrozole, Palbociclib | I/II | 54 ** | https://ClinicalTrials.gov/show/NCT03774472, accessed on 1 October 2021 |
| NCT01480154 | Malignant solid neoplasms (advanced), cutaneous melanoma, prostate cancer, renal cell cancer | HCQ | Akt Inhibitor MK2206 | I | 62 * | https://ClinicalTrials.gov/show/NCT01480154, accessed on 1 October 2021 |
| NCT04527549 | Melanoma (advanced) | HCQ | Placebo, Trametinib, Dabrafenib | II | 84 ** | https://ClinicalTrials.gov/show/NCT04527549, accessed on 1 October 2021 |
| NCT04841148 | Breast cancer | HCQ | Avelumab, Palbociclib | II | 96 ** | https://ClinicalTrials.gov/show/NCT04841148, accessed on 1 October 2021 |
| NCT03979651 | Melanoma (metastatic NRAS) | HCQ | Trametinib | N/A | 29 ** | https://ClinicalTrials.gov/show/NCT03979651, accessed on 1 October 2021 |
| NCT03598595 | Osteosarcoma (recurrent, refractory) | HCQ | Docetaxel, Gemcitabine | I/II | 31 ** | https://ClinicalTrials.gov/show/NCT03598595, accessed on 1 October 2021 |